Patents by Inventor Jeyaraj Duraiswamy
Jeyaraj Duraiswamy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190185478Abstract: The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein R1 represents H; optionally substituted alkyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkoxy, NH2, —NHC1-3alkyl and —N(C1-3alkyl)2); —C(O)Oalkyl; haloalkyl; haloalkoxy; or -alkylaryl; each R2 independently represents H; optionally substituted alkyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkoxy, NH2, —NHC1-3alkyl and —N(C1-3alkyl)2); -alkylaryl; optionally substituted carbocyclyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkyl, C1-6alkoxy, C1-6haloalkyl, C1-6haloalkoxy and halo); optionally substituted heterocyclyl (wherein optional substituents include one or more substituents each independentlType: ApplicationFiled: December 19, 2018Publication date: June 20, 2019Applicant: Agency for Science, Technology and ResearchInventors: Jenefer Alam, Soo Yei Ho, Wei Ling Wang, Athisayamani Jeyaraj Duraiswamy
-
Patent number: 10189842Abstract: The present invention relates to dihydropyrazolo[1,5-a]pyrimidine compounds of formula I, defined herein, as WNT pathways modulators, processes for making them, and pharmaceutical compositions comprising them. Methods of treatment of conditions mediated by WNT pathway signalling including cancer, fibrosis, stem cell and diabetic retinopathy, rheumatoid arthritis, psoriasis and myocardial infarction, comprising the compounds of formula I are also provided.Type: GrantFiled: December 17, 2014Date of Patent: January 29, 2019Assignee: Agency for Science, Technology and ResearchInventors: Jenefer Alam, Soo Yei Ho, Wei Ling Wang, Athisayamani Jeyaraj Duraiswamy
-
Publication number: 20180208600Abstract: The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, Alzheimer's disease), as well as methods of treating these diseases.Type: ApplicationFiled: January 16, 2018Publication date: July 26, 2018Applicant: Agency for Science, Technology and ResearchInventors: Kassoum Nacro, Athisayamani Jeyaraj Duraiswamy, Lohitha Rao Chennamaneni
-
Publication number: 20180170932Abstract: The invention relates to the use of compounds of general structure (I) in modulation of the Wnt pathway [Formula should be inserted here] wherein R1, R2, R3, R4 and R5 are each, independently, H or an alkyl group; D is selected from the group consisting of H, halogen, alkyl, cycloalkyl, aryl, and dialkylamino, each (other than H and halogen) being optionally substituted; Ar is an aryl or heteroaryl group, optionally substituted; Cy is an aryl, heteroaryl or a saturated ring containing at least one heteroatom, each being optionally substituted; and n is an integer from 1 to 3.Type: ApplicationFiled: February 20, 2018Publication date: June 21, 2018Applicant: Agency for Science, Technology and ResearchInventors: Soo Yei Ho, Stephanie Eliane BLANCHARD, Athisayamani Jeyaraj DURAISWAMY, Jenefer ALAM, Vikrant Arun ADSOOL
-
Patent number: 9981964Abstract: The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein R1 represents optionally substituted alkyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkoxy); optionally substituted carbocyclyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkyl, C1-6alkoxy, C1-6haloalkyl, C1-6haloalkoxy and halo); or -alkylaryl; R2 represents H; or alkyl; R3 represents H; or alkyl; U, V and W represent —(CH2)—; or U and V together represent —CH?CH— and W represents C?O; Y represents aryl; heteroaryl; optionally substituted carbocyclyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkyl, C1-6alkoxy, C1-6haloalkyl, C1-6haloalkoxy and halo); or optionally substituted heterocyclyl (wherein optiType: GrantFiled: December 17, 2014Date of Patent: May 29, 2018Assignee: Agency for Science, Technology and ResearchInventors: Jenefer Alam, Anders Poulsen, Soo Yei Ho, Wei Ling Wang, Athisayamani Jeyaraj Duraiswamy
-
Publication number: 20180093988Abstract: The present invention relates to dihydropyrazolo[1,5-a]pyrimidine compounds of formula I, defined herein, as WNT pathways modulators, processes for making them, and pharmaceutical compositions comprising them. Methods of treatment of conditions mediated by WNT pathway signalling including cancer, fibrosis, stem cell and diabetic retinopathy, rheumatoid arthritis, psoriasis and myocardial infarction, comprising the compounds of formula I are also provided.Type: ApplicationFiled: December 17, 2014Publication date: April 5, 2018Applicant: Agency for Science, Technolgy and ResearchInventors: Jenefer Alam, Soo Yei Ho, Wei Ling Wang, Athisayamani Jeyaraj Duraiswamy
-
Patent number: 9926320Abstract: The invention relates to the use of compounds of general structure (I) in modulation of the Wnt pathway [Formula should be inserted here] wherein R1, R2, R3, R4 and R5 are each, independently, H or an alkyl group; D is selected from the group consisting of H, halogen, alkyl, cycloalkyl, aryl, and dialkylamino, each (other than H and halogen) being optionally substituted; Ar is an aryl or heteroaryl group, optionally substituted; Cy is an aryl, heteroaryl or a saturated ring containing at least one heteroatom, each being optionally substituted; and n is an integer from 1 to 3.Type: GrantFiled: May 19, 2014Date of Patent: March 27, 2018Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Soo Yei Ho, Stephanie Eliane Blanchard, Athisayamani Jeyaraj Duraiswamy, Jenefer Alam, Vikrant Arun Adsool
-
Patent number: 9908886Abstract: The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, Alzheimer's disease), as well as methods of treating these diseases.Type: GrantFiled: April 1, 2013Date of Patent: March 6, 2018Assignee: Agency for Science, Technology and ResearchInventors: Kassoum Nacro, Athisayamani Jeyaraj Duraiswamy, Lohitha Rao Chennamaneni
-
Publication number: 20170334912Abstract: The invention relates to the use of compounds of general structure (I) in modulation of the Wnt pathway [Formula should be inserted here] wherein R1, R2, R3, R4 and R5 are each, independently, H or an alkyl group; D is selected from the group consisting of H, halogen, alkyl, cycloalkyl, aryl, and dialkylamino, each (other than H and halogen) being optionally substituted; Ar is an aryl or heteroaryl group, optionally substituted; Cy is an aryl, heteroaryl or a saturated ring containing at least one heteroatom, each being optionally substituted; and n is an integer from 1 to 3.Type: ApplicationFiled: August 3, 2017Publication date: November 23, 2017Inventors: Soo Yei Ho, Stephanie Eliane Blanchard, Athisayamani Jeyaraj Duraiswamy, Jenefer Alam, Vikrant Arun Adsool
-
Publication number: 20170240550Abstract: The present invention relates to dihydropyrazolo[1,5-a]pyrimidine compounds of formula I, defined herein, as WNT pathways modulators, processes for making them, and pharmaceutical compositions comprising them. Methods of treatment of conditions mediated by WNT pathway signalling including cancer, fibrosis, stem cell and diabetic retinopathy, rheumatoid arthritis, psoriasis and myocardial infarction, comprising the compounds of formula I are also provided.Type: ApplicationFiled: December 17, 2014Publication date: August 24, 2017Applicant: Agency for Science, Technolgy and ResearchInventors: Jenefer Alam, Soo Yei Ho, Wei Ling Wang, Athisayamani Jeyaraj Duraiswamy
-
Publication number: 20160318926Abstract: The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein R1 represents optionally substituted alkyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkoxy); optionally substituted carbocyclyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkyl, C1-6alkoxy, C1-6haloalkyl, C1-6haloalkoxy and halo); or -alkylaryl; R2 represents H; or alkyl; R3 represents H; or alkyl; U, V and W represent —(CH2)—; or U and V together represent —CH?CH— and W represents C?O; Y represents aryl; heteroaryl; optionally substituted carbocyclyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkyl, C1-6alkoxy, C1-6haloalkyl, C1-6haloalkoxy and halo); or optionally substituted heterocyclyl (wherein optiType: ApplicationFiled: December 17, 2014Publication date: November 3, 2016Applicant: Agency for Science, Technology and ResearchInventors: Jenefer Alam, Anders Poulsen, Soo Yei Ho, Wei Ling Wang, Athisayamani Jeyaraj Duraiswamy
-
Publication number: 20160311829Abstract: The present invention relates to dihydropyrazolo[1,5-a]pyrimidine compounds of formula I, defined herein, as WNT pathways modulators, processes for making them, and pharmaceutical compositions comprising them. Methods of treatment of conditions mediated by WNT pathway signalling including cancer, fibrosis, stem cell and diabetic retinopathy, rheumatoid arthritis, psoriasis and myocardial infarction, comprising the compounds of formula I are also provided.Type: ApplicationFiled: December 17, 2014Publication date: October 27, 2016Applicant: Agency for Science, Technolgy and ResearchInventors: Jenefer Alam, Soo Yei Ho, Wei Ling Wang, Athisayamani Jeyaraj Duraiswamy
-
Publication number: 20160090386Abstract: The invention relates to the use of compounds of general structure (I) in modulation of the Wnt pathway [Formula should be inserted here] wherein R1, R2, R3, R4 and R5 are each, independently, H or an alkyl group; D is selected from the group consisting of H, halogen, alkyl, cycloalkyl, aryl, and dialkylamino, each (other than H and halogen) being optionally substituted; Ar is an aryl or heteroaryl group, optionally substituted; Cy is an aryl, heteroaryl or a saturated ring containing at least one heteroatom, each being optionally substituted; and n is an integer from 1 to 3.Type: ApplicationFiled: May 19, 2014Publication date: March 31, 2016Applicant: Agency for Science, Technology and ResearchInventors: Soo Yei Ho, Stephanie Eliane Blanchard, Athisayamani Jeyaraj Duraiswamy, Jenefer Alam, Vikrant Arun Adsool
-
Publication number: 20140371199Abstract: The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, Alzheimer's disease), as well as methods of treating these diseases.Type: ApplicationFiled: April 1, 2013Publication date: December 18, 2014Applicant: Agency for Science, Technology and ResearchInventors: Kassoum Nacro, Athisayamani Jeyaraj Duraiswamy, Lohitha Rao
-
Patent number: 8278282Abstract: This invention relates to novel compounds that have various medicinal applications, e.g. for the treatment and/or prevention of viral infections.Type: GrantFiled: February 7, 2008Date of Patent: October 2, 2012Assignee: Novartis AGInventors: Zheng Yin, Jeyaraj Duraiswamy, Yen Liang Chen
-
Publication number: 20100227833Abstract: This invention relates to novel compounds that have various medicinal applications, e.g. for the treatment and/or prevention of viral infections.Type: ApplicationFiled: February 7, 2008Publication date: September 9, 2010Applicant: NOVARTIS PHARMA AGInventors: Zheng Yin, Jeyaraj Duraiswamy, Yen Liang Chen
-
Publication number: 20100144655Abstract: This invention relates to novel compounds that have various medicinal applications, e.g. for the treatment and/or prevention of viral infections.Type: ApplicationFiled: August 6, 2009Publication date: June 10, 2010Applicant: NOVARTIS AGInventors: Yen Liang CHEN, Jeyaraj DURAISWAMY, Sarah HALLER, Matthias KEIM, Ravinder Reddy KONDREDDI, Zheng YIN
-
Publication number: 20090318445Abstract: The invention relates to novel compounds that are inhibitors of peptidyl deformylase (PDF). The compounds are useful as antimicrobials and antibiotics. The compounds of the invention display selective inhibition of peptidyl deformylase versus other metalloproteinases such as MMPs. Methods of preparation and uses of the compounds are also disclosed.Type: ApplicationFiled: December 28, 2006Publication date: December 24, 2009Applicants: NORVARTIS AG, NOVARTIS PHARMA GMBHInventors: Arkadius Pichota, Jeyaraj Duraiswamy, Zheng Yin, Thomas Hugo Keller, Mark Schreiber